NASDAQ:MDXG - MiMedx Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.33 +0.11 (+3.42 %)
(As of 07/18/2018 02:40 AM ET)
Previous Close$3.22
Today's Range$3.19 - $3.44
52-Week Range$3.01 - $18.25
Volume2.69 million shs
Average Volume3.22 million shs
Market Capitalization$374.19 million
P/E Ratio16.05
Dividend YieldN/A
MiMedx Group logoMiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Receive MDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio16.05
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$245.01 million
Price / Sales1.51
Cash Flow$0.1796 per share
Price / Cash18.54
Book Value$1.21 per share
Price / Book2.75


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares111,040,000
Market Cap$374.19

The Truth About Cryptocurrencies

MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

How will MiMedx Group's stock buyback program work?

MiMedx Group declared that its board has approved a share repurchase plan on Wednesday, December 13th 2017, which allows the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company's board believes its stock is undervalued.

How were MiMedx Group's earnings last quarter?

MiMedx Group Inc (NASDAQ:MDXG) posted its earnings results on Thursday, October, 26th. The medical equipment provider reported $0.08 EPS for the quarter, meeting analysts' consensus estimates of $0.08. The medical equipment provider earned $84.60 million during the quarter, compared to the consensus estimate of $84.60 million. The company's revenue was up 31.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.06 earnings per share. View MiMedx Group's Earnings History.

What price target have analysts set for MDXG?

4 brokers have issued 1-year price objectives for MiMedx Group's shares. Their predictions range from $9.00 to $21.00. On average, they expect MiMedx Group's stock price to reach $16.00 in the next year. This suggests a possible upside of 380.5% from the stock's current price. View Analyst Ratings for MiMedx Group.

What is the consensus analysts' recommendation for MiMedx Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about MiMedx Group stock?

Here are some recent quotes from research analysts about MiMedx Group stock:
  • 1. Needham & Company LLC analysts commented, "This morning (3/15/18), MDXG issued a press release announcing: 1) management expects 1Q18 revenue to exceed the high end of their guidance range and reiterates their 2018 guidance and 2) the U.S. Department of Justice (DOJ) is reviewing the SEC investigation matters. While MDXG’s business appears to be performing well despite the controversy swirling around the company, we believe investors may continue to heavily discount the fundamentals until more is known about the outcome of the Audit Committee’s investigation, the SEC investigation, and the DOJ review." (3/15/2018)
  • 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (12/8/2017)

Are investors shorting MiMedx Group?

MiMedx Group saw a drop in short interest in June. As of June 29th, there was short interest totalling 47,825,907 shares, a drop of 6.0% from the June 15th total of 50,864,881 shares. Based on an average daily trading volume, of 2,182,417 shares, the days-to-cover ratio is currently 21.9 days. Approximately 46.6% of the company's stock are sold short. View MiMedx Group's Current Options Chain.

Who are some of MiMedx Group's key competitors?

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the folowing people:
  • Mr. Parker H. Petit, Chairman and Chief Exec. Officer (Age 79)
  • Mr. William Charles Taylor, Pres, Chief Operating Officer and Director (Age 50)
  • Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
  • Mr. Edward J. Borkowski, Interim Chief Financial Officer (Age 60)
  • Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)

Has MiMedx Group been receiving favorable news coverage?

News articles about MDXG stock have trended positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MiMedx Group earned a media sentiment score of 0.35 on Accern's scale. They also gave media headlines about the medical equipment provider an impact score of 46.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Thompson Investment Management Inc. (0.53%) and Summit Creek Advisors LLC (0.36%). View Institutional Ownership Trends for MiMedx Group.

Which institutional investors are selling MiMedx Group stock?

MDXG stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC. View Insider Buying and Selling for MiMedx Group.

Which institutional investors are buying MiMedx Group stock?

MDXG stock was acquired by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc.. View Insider Buying and Selling for MiMedx Group.

How do I buy shares of MiMedx Group?

Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $3.33.

How big of a company is MiMedx Group?

MiMedx Group has a market capitalization of $374.19 million and generates $245.01 million in revenue each year. MiMedx Group employs 690 workers across the globe.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]

MarketBeat Community Rating for MiMedx Group (NASDAQ MDXG)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  509
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.